Literature DB >> 8094016

Relationship of deoxycytidine kinase and cytoplasmic 5'-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine.

H Kawasaki1, C J Carrera, L D Piro, A Saven, T J Kipps, D A Carson.   

Abstract

The agent 2-chlorodeoxyadenosine (2-CdA) has chemotherapeutic activity in hairy cell leukemia (HCL) and in refractory chronic lymphocytic leukemia (CLL). The cytotoxic activity of 2-CdA requires the intracellular accumulation of 2-CdA nucleotides. Deoxycytidine kinase (dCK) and cytoplasmic 5'-nucleotidase (5'-NT) are the principal enzymes that phosphorylate 2-CdA and dephosphorylate 2-CdA 5'-monophosphate, respectively. The net accumulation of 2-CdA nucleotides may therefore depend on both dCK and 5'-NT. The purpose of the present experiments was to determine if there is a relationship between pretreatment levels of dCK and 5'-NT in HCL and in CLL cells, and the clinical outcome of 2-CdA treatment. As measured by a direct immunoassay for dCK in 25 CLL patients, and by a 5'-NT activity assay in 23 patients, mean dCK levels were significantly higher in 2-CdA responders than in nonresponders (P < .01), whereas mean 5'-NT levels were significantly lower in 2-CdA responders than in nonresponders (P < .05). Mean dCK levels were higher in six HCL 2-CdA responders than in one nonresponder, whereas mean 5'-NT levels were lower in the 2-CdA responders than in the nonresponder. These results suggest that both dCK and 5'-NT are determinants of 2-CdA responsiveness.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8094016

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  29 in total

1.  Quantitation of synergism of arabinosylcytosine and cladribine against the growth of arabinosylcytosine-resistant human lymphoid cells.

Authors:  Tieran Han; Marilyn Fernandez; Ting-Chao Chou; Ram P Agarwal
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

Review 2.  Cladribine to Treat Relapsing Forms of Multiple Sclerosis.

Authors:  Gavin Giovannoni
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 3.  Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 2.

Authors:  Aryan Rafiee Zadeh; Keyvan Ghadimi; Akram Ataei; Mozhde Askari; Neda Sheikhinia; Nooshin Tavoosi; Masih Falahatian
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2019-08-15

Review 4.  [Oral cladribine for relapsing-remitting multiple sclerosis: another purine analogue or a genuine therapeutic innovation?].

Authors:  S Schmidt
Journal:  Nervenarzt       Date:  2010-10       Impact factor: 1.214

5.  Characterization of the deoxycytidine kinase promoter in human lymphoblast cell lines.

Authors:  E H Chen; E E Johnson; S M Vetter; B S Mitchell
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

6.  Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis.

Authors:  Kenneth P Johnson
Journal:  Ther Clin Risk Manag       Date:  2010-04-15       Impact factor: 2.423

Review 7.  Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.

Authors:  Clemens Warnke; Heinz Wiendl; Hans-Peter Hartung; Olaf Stüve; Bernd C Kieseier
Journal:  Drug Des Devel Ther       Date:  2010-07-21       Impact factor: 4.162

Review 8.  Development of oral cladribine for the treatment of multiple sclerosis.

Authors:  Hans-Peter Hartung; Orhan Aktas; Bernd Kieseier; Giancarlo Comi Giancarlo Comi
Journal:  J Neurol       Date:  2010-02       Impact factor: 4.849

9.  Induction of an apoptotic program in cell-free extracts by 2-chloro-2'-deoxyadenosine 5'-triphosphate and cytochrome c.

Authors:  L M Leoni; Q Chao; H B Cottam; D Genini; M Rosenbach; C J Carrera; I Budihardjo; X Wang; D A Carson
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

10.  Elucidation of different binding modes of purine nucleosides to human deoxycytidine kinase.

Authors:  Elisabetta Sabini; Saugata Hazra; Manfred Konrad; Arnon Lavie
Journal:  J Med Chem       Date:  2008-06-21       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.